Clinical Trials of Cannabidiol for Substance Use Disorders: Outcome Measures, Surrogate Endpoints, and Biomarkers

Background: Cannabidiol (CBD) is a cannabinoid of potential interest for the treatment of substance use disorders. Our aim was to review the outcome measures, surrogate endpoints, and biomarkers in published and ongoing randomized clinical trials. Methods: We conducted a search in PubMed, Web of Sci...

Descripción completa

Detalles Bibliográficos
Autores principales: Morel, Alix, Lebard, Pierre, Dereux, Alexandra, Azuar, Julien, Questel, Frank, Bellivier, Frank, Marie-Claire, Cynthia, Fatséas, Mélina, Vorspan, Florence, Bloch, Vanessa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Psychiatry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937926/
https://www.ncbi.nlm.nih.gov/pubmed/33692705
http://dx.doi.org/10.3389/fpsyt.2021.565617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937926/
https://www.ncbi.nlm.nih.gov/pubmed/33692705
http://dx.doi.org/10.3389/fpsyt.2021.565617

Ejemplares similares